RxDoctor Payments Data

Kabul Singh, MD

Internal Medicine · Flushing, NYNPI 1386602175

Payments from drug & device makers

$1,918in general payments, 2019–2025

Across 29 payments — averaging $66.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$394
  • Mallinckrodt Hospital Products Inc.$327
  • AstraZeneca$250
  • Novo Nordisk$148
  • Intuity Medical Inc$147
  • Amgen$137
  • plus $514 from 6 others

What the payments were for

  • Food & beverage$1,918100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,918 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$68,942
Medicare patients
80
Services billed
915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate92$73,134
JanumetSitagliptin Phos/Metformin Hcl73$60,119
JardianceEmpagliflozin48$46,051
FarxigaDapagliflozin Propanediol38$34,917
EliquisApixaban21$24,824
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,187
Spiriva HandihalerTiotropium Bromide14$6,743
Metoprolol Succinate201$2,424
Albuterol Sulfate HfaAlbuterol Sulfate36$1,972
Losartan Potassium255$1,785
Repaglinide70$1,785
Atorvastatin Calcium318$1,777
Levothyroxine Sodium129$1,440
Wixela InhubFluticasone Propion/Salmeterol13$1,366
Fluticasone Propionate122$1,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$394$46,05148 claims
AstraZenecaFarxiga$250$34,91738 claims
AbbVieSynthroid$35$1,14318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →